KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Issued (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Shares Issued for 10 consecutive years, with -$258.7 million as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 13593.11% to -$258.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$114.0 million through Dec 2025, down 464.32% year-over-year, with the annual reading at $27.9 million for FY2025, 10.72% down from the prior year.
  • Shares Issued hit -$258.7 million in Q4 2025 for CRISPR Therapeutics AG, down from $71.3 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $254.5 million in Q2 2024 to a low of -$258.7 million in Q4 2025.
  • Historically, Shares Issued has averaged $1.4 million across 5 years, with a median of $16.2 million in 2021.
  • Biggest five-year swings in Shares Issued: surged 1048.2% in 2024 and later crashed 13593.11% in 2025.
  • Year by year, Shares Issued stood at $6.3 million in 2021, then skyrocketed by 481.87% to $36.7 million in 2022, then decreased by 10.73% to $32.7 million in 2023, then plummeted by 94.14% to $1.9 million in 2024, then plummeted by 13593.11% to -$258.7 million in 2025.
  • Business Quant data shows Shares Issued for CRSP at -$258.7 million in Q4 2025, $71.3 million in Q3 2025, and $71.3 million in Q2 2025.